As shown in Figure 3A, RT+TLR9 agonist treatment induced a potent IgG antibody response against 3LL tumor, as analyzed by indirect ELISA with 3LL tumor lysate coated as antigen on the ELISA plates. The gene discussed is TLR9; the disease is neoplasm.